drugset / Trial / NCT01876628
Adjunctive Clindamycin for Cellulitis: C4C Trial.
Phase 4
Completed
410 enrolled
University Hospitals Bristol and Weston NHS Foundation Trust
Public Health England · collabUniversity of Bristol · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this study is to see whether the addition of Clindamycin, a protein inhibiting antibiotic, to the standard antibiotic treatment of limb cellulitis, with Flucloxacillin, results in less tissue damage and a more rapid resolution of both systemic and local features, in a cost-effective manner. This study is a randomised controlled trial comparing Clindamycin with placebo.
Timeline
- Start
- 2013-10
- Primary completion
- 2015-12
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clindamycin | Unknown | 300 mg | Oral |
| Comparator | FLOXACILLIN | Small molecule | 500 mg | Intravenous |